Yvonne Naegelin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3025117/publications.pdf

Version: 2024-02-01

65 papers	3,870 citations	172457 29 h-index	128289 60 g-index
66 all docs	66 docs citations	66 times ranked	5803 citing authors

#	Article	IF	Citations
1	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
2	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
3	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018, 141, 2382-2391.	7.6	345
4	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
5	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 410-418.	1.9	111
6	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
7	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1290-1296.	3.0	103
8	Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy and Behavior, 2008, 12, 477-480.	1.7	102
9	Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum. ENeuro, 2018, 5, ENEURO.0419-17.2018.	1.9	95
10	Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis â€" A longitudinal voxel-based morphometry study. NeuroImage, 2009, 45, 60-67.	4.2	83
11	Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1560-1569.	3.0	82
12	Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2016, 12, 466-477.	2.7	78
13	The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 356-364.	3.0	76
14	Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis. PLoS ONE, 2014, 9, e86916.	2.5	73
15	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology, 2021, 89, 610-616.	5.3	68
16	Spinal cord volume loss. Neurology, 2018, 91, e349-e358.	1.1	66
17	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2019, 76, 274.	9.0	56
18	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. Radiology, 2013, 269, 542-552.	7.3	52

#	Article	IF	Citations
19	Multivariate pattern classification of gray matter pathology in multiple sclerosis. NeuroImage, 2012, 60, 400-408.	4.2	47
20	Preferential spinal cord volume loss in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 947-957.	3.0	44
21	Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsingâ€remitting multiple sclerosis. Human Brain Mapping, 2010, 31, 1542-1555.	3.6	42
22	Longitudinal gray matter changes in multiple sclerosisâ€”Differential scanner and overall diseaseâ€related effects. Human Brain Mapping, 2012, 33, 1225-1245.	3.6	40
23	Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology, 2012, 259, 2401-2413.	3.6	37
24	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. Journal of Neurology, 2020, 267, 1536-1546.	3.6	35
25	Labelâ€fusionâ€segmentation and deformationâ€based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability. Human Brain Mapping, 2014, 35, 4193-4203.	3.6	34
26	Clinical studies and antiâ€inflammatory mechanisms of treatments. Epilepsia, 2017, 58, 69-82.	5.1	34
27	Effect of immunomodulatory medication on regional gray matter loss in relapsingâ€“remitting multiple sclerosisâ€”A longitudinal MRI study. Brain Research, 2010, 1325, 174-182.	2.2	31
28	Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial. PLoS ONE, 2014, 9, e86663.	2.5	31
29	Beta Activity in Status Epilepticus. Epilepsia, 2006, 47, 207-210.	5.1	30
30	Progression in disability and regional grey matter atrophy in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 202-213.	3.0	30
31	3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. Multiple Sclerosis Journal, 2012, 18, 1570-1576.	3.0	29
32	Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. Journal of Neurology, 2012, 259, 2673-2680.	3.6	27
33	Spatiotemporal distribution of white matter lesions in relapsingâ€“remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1577-1584.	3.0	26
34	Longitudinal patterns of cortical thinning in multiple sclerosis. Human Brain Mapping, 2020, 41, 2198-2215.	3.6	26
35	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
36	Levels of brainâ€derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2251-2261.	3.7	23

#	Article	IF	Citations
37	Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. Human Brain Mapping, 2019, 40, 4091-4104.	3.6	22
38	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	3.7	21
39	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. Journal of Medical Internet Research, 2021, 23, e30394.	4.3	21
40	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 281-288.	3.0	20
41	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	3.0	19
42	Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. Brain, 2008, 131, 1776-1782.	7.6	18
43	Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 1909-1917.	3.6	18
44	Efficacy and Safety of Fingolimod in an Unselected Patient Population. PLoS ONE, 2016, 11, e0146190.	2.5	18
45	Clinical EEG in cognitively impaired patients with Parkinson's Disease. Journal of the Neurological Sciences, 2011, 310, 75-78.	0.6	17
46	Cerebrospinal fluid from Alzheimerâ€™s disease patients promotes tau aggregation in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 72.	5.2	16
47	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	5.3	16
48	Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis. Brain Topography, 2014, 27, 318-327.	1.8	15
49	Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome. Metabolites, 2022, 12, 291.	2.9	14
50	MRI characteristics of periaqueductal lesions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 542-551.	2.0	13
51	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). Journal of Neurology, 2016, 263, 1364-1374.	3.6	13
52	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 14-20.	2.0	13
53	Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. European Journal of Radiology, 2013, 82, e848-e852.	2.6	12
54	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. Journal of Neurology, 2020, 267, 192-202.	3.6	12

#	Article	IF	Citations
55	Growth differentiation factor 15 is increased in stable MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
56	Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet Journal of Rare Diseases, 2021, 16, 19.	2.7	12
57	Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. International Journal of Molecular Sciences, 2016, 17, 489.	4.1	11
58	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	3.6	10
59	Central nervous system atrophy predicts future dynamics of disability progression in a realâ€world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	3.3	10
60	Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum, 2022, 21, 632-646.	2.5	8
61	Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations. NeuroImage, 2015, 108, 87-94.	4.2	6
62	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. European Neurology, 2018, 80, 207-214.	1.4	5
63	Multiple Sclerosis: Associations Between Physical Disability and Depression Are Not Mediated by Self-Reported Physical Activity. Perceptual and Motor Skills, 2017, 124, 974-991.	1.3	4
64	Acute Vertigo with Double Vision â€“ Brainstem Stroke or Stroke Mimic?. Cerebrovascular Diseases, 2010, 30, 626-627.	1.7	3
65	Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 366-368.	3.0	2